🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,027 results for “ERA” Clear

  1. APF530

    Heron Therapeutics

    Chemotherapy-induced Nausea and Vomiting

    phase 3 small molecule completed

    1 trial

  2. APF530

    Heron Therapeutics

    Nausea and Vomiting

    phase 3 small molecule completed

    1 trial

  3. APL-2

    Lacuna Pharma Pty Ltd

    Geographic Atrophy Secondary to Age-Related Macular Degeneration

    phase 3 small molecule active

    1 trial

  4. APL-2, Pegcetacoplan

    Apellis Europe B.V.

    Geographic Atrophy Secondary to Age-related Macular Degeneration

    phase 3 small molecule completed

    1 trial

  5. APR-246 + azacitidine

    Aprea Therapeutics

    MDS

    phase 3 small molecule completed

    1 trial

  6. ARCT-154 Self-Amplifying RNA SARS-CoV-2 Vaccine

    Arcturus Therapeutics Holdings

    COVID-19 Vaccines

    phase 3 mab completed

    1 trial

  7. ARCT-2303

    Arcturus Therapeutics Holdings

    COVID-19

    phase 3 mab completed

    1 trial

  8. ARD-101

    Ark Therapeutics

    Hyperphagia

    phase 3 small molecule on hold

    1 trial

  9. ARGX-113, Vyvgart 20 mg/mL concentrate for solution for infusion, Vyvgart 1 000 mg solution for injection

    argenx

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  10. ARQ-151 0.3% cream

    Arcutis Biotherapeutics

    Chronic Plaque Psoriasis

    phase 3 small molecule completed

    1 trial

  11. ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%

    Arcutis Biotherapeutics

    Atopic Dermatitis Eczema

    phase 3 small molecule completed

    1 trial

  12. ASSURE: An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects with Primary Biliary Cholangitis (PBC)

    Gilead Sciences Pty Limited

    Primary Biliary Cholangitis

    phase 3 other active

    1 trial

  13. AT2221

    AMICUS THERAPEUTICS PTY LTD

    Pompe Disease (Late-onset)

    phase 3 small molecule completed

    1 trial

  14. AT2221, ATB200

    AMICUS THERAPEUTICS PTY LTD

    Adult Subjects With Late Onset Pompe Disease (LOPD)

    phase 3 small molecule active

    1 trial

  15. AVELUMAB, DOSTARLIMAB, ATEZOLIZUMAB, AVELUMAB, CEMIPLIMAB, DOSTARLIMAB, NIVOLUMAB, PEMBROLIZUMAB, NIVOLUMAB, DURVALUMAB, CEMIPLIMAB, ATEZOLIZUMAB, PEMBROLIZUMAB, DURVALUMAB

    Ningbo Cancer Hospital

    Only patients with oncologic locally advanced or metastatic tumour (lung cancer, renal cell cancer (except IMDC favorable-risk treated Tyrosine Kinase Inhibitor [TKI] / immunotherapy [IO] combination), head and neck cancer, urothelial carcinoma, triple negative breast cancer, Merkel cancer, melanoma, hepatocellular carcinoma, colorectal carcinoma with microsatellite instability [MSI], esophageal squamous cell carcinoma, endometrial carcinoma, or cervical cancer, gastric/gastro-esophageal junction/esophageal adenocarcinoma, basal cell carcinoma or squamous skin carcinoma) in partial or complete response (except for melanoma, only patients in partial response) after 6 months of standard IO treatment (monotherapy or previously in combination with other immunotherapy (ipilimumab) or chemotherapy or continuous combination with pemetrexed or bevacizumab or TKI).

    phase 3 small molecule active

    1 trial

  16. AXS-02

    Axsome Therapeutics

    Osteoarthritis, Knee

    phase 3 small molecule active

    1 trial

  17. AXS-02 (oral zoledronate)

    Axsome Therapeutics

    Complex Regional Pain Syndrome

    phase 3 small molecule active

    1 trial

  18. AXS-05

    Axsome Therapeutics

    Agitation in Patients With Dementia of the Alzheimer's Type

    phase 3 small molecule completed

    3 trials

  19. AXS-05

    Axsome Therapeutics

    Treatment Resistant Major Depressive Disorder

    phase 3 small molecule completed

    1 trial

  20. AXS-05

    Axsome Therapeutics

    Depression

    phase 3 small molecule completed

    1 trial

  21. AXS-05 (dextromethorphan and bupropion) oral tablets

    Axsome Therapeutics

    Major Depressive Disorder

    phase 3 small molecule completed

    1 trial

  22. AXS-05 (dextromethorphan-bupropion)

    Axsome Therapeutics

    Agitation in Patients With Dementia of the Alzheimer's Type

    phase 3 small molecule completed

    2 trials

  23. AXS-07

    Axsome Therapeutics

    Migraine

    phase 3 small molecule completed

    1 trial

  24. AXS-07 (MoSEIC meloxicam and rizatriptan)

    Axsome Therapeutics

    Migraine

    phase 3 small molecule completed

    2 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources